Autolus Therapeutics plc announced the presentation of preliminary data from the Phase 1 CATULUS trial of obe-cel in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), as well as additional analyses from the registrational FELIX study in adult r/r B-ALL, at the American Society of Hematology $(ASH)$ Annual Meeting. The CATULUS trial data showed a 95.5% overall response rate in pediatric patients, including those with high-risk relapse and primary CNS relapse, with low rates of high-grade cytokine release syndrome $(CRS)$ and immune effector cell-associated neurotoxicity syndrome (ICANS). The FELIX study highlighted product cell phenotype and CAR T-cell persistence at three months as potential predictors of long-term remission. Real-world data from the US commercial launch of obe-cel, collected by the ROCCA consortium, demonstrated high response rates and low levels of high-grade CRS and ICANS, consistent with clinical trial findings.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autolus Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598490-en) on December 08, 2025, and is solely responsible for the information contained therein.
Comments